Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Sarah B. Goldberg"'
Autor:
Michael Hwang, Yen Lin Chia, Yanan Zheng, Cecil Chi‐Keung Chen, Jimmy He, Xuyang Song, Diansong Zhou, Sarah B. Goldberg, Lillian L. Siu, David Planchard, Solange Peters, Helen Mann, Lee Krug, Caroline Even
Publikováno v:
British Journal of Clinical Pharmacology. 89:1601-1616
Tremelimumab, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) human monoclonal antibody of the immunoglobulin G2 kappa isotype, has been studied in oncology clinical trials as both monotherapy and in combination with durvalumab. This study cha
Autor:
Daniel Morgensztern, Daniel Boffa, Alexander Chen, Andrew Dhanasopon, Sarah B. Goldberg, Roy H. Decker, Siddhartha Devarakonda, Jane P. Ko, Luisa M. Solis Soto, Saiama N. Waqar, Ignacio I. Wistuba, Roy S. Herbst
Publikováno v:
Holland‐Frei Cancer Medicine. :1-29
Autor:
Alcida Karz, Maya Dimitrova, Kevin Kleffman, Christopher Alvarez‐Breckenridge, Michael B. Atkins, Adrienne Boire, Marcus Bosenberg, Priscilla Brastianos, Daniel P. Cahill, Qing Chen, Sherise Ferguson, Peter Forsyth, Isabella C. Glitza Oliva, Sarah B. Goldberg, Sheri L. Holmen, Jonathan P. S. Knisely, Glenn Merlino, Don X. Nguyen, Michael E. Pacold, Eva Perez‐Guijarro, Keiran S. M. Smalley, Hussein A. Tawbi, Patrick Y. Wen, Michael A. Davies, Harriet M. Kluger, Janice M. Mehnert, Eva Hernando
Publikováno v:
Pigment Cell Melanoma Res
Brain metastases are the most common brain malignancy. This review discusses the studies presented at the third annual meeting of the Melanoma Research Foundation in the context of other recent reports on the biology and treatment of melanoma brain m
Autor:
Jacqueline H. Starrett, Kamrine E. Poels, Mark A. Lemmon, Alexandra Kuhlmann, Amy Nagelberg, Kristin Price, Iris K. van Alderwerelt van Rosenburgh, Kumar Dilip Ashtekar, Arun M. Unni, Paul D. Smith, Hina Khan, Deborah Ayeni, Dylan Farnsworth, Susan M. Kaech, Sarah B. Goldberg, Robert J. Homer, Maria Emanuela Cuomo, Franziska Michor, Mmaserame Gaefele, William W. Lockwood, Alexis A. Guernet, Darren Cross, Katerina Politi, Tyler F. Stewart
Publikováno v:
The FASEB Journal. 34:1-1
Osimertinib, a mutant-specific third-generation EGFR tyrosine kinase inhibitor, is emerging as the preferred first-line therapy for EGFR-mutant lung cancer, yet resistance inevitably develops in patients. We modeled acquired resistance to osimertinib